JP2022512689A5 - - Google Patents

Info

Publication number
JP2022512689A5
JP2022512689A5 JP2021520223A JP2021520223A JP2022512689A5 JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5 JP 2021520223 A JP2021520223 A JP 2021520223A JP 2021520223 A JP2021520223 A JP 2021520223A JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5
Authority
JP
Japan
Prior art keywords
gene therapy
therapy vector
vector according
protein
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512689A (ja
JP7577650B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055679 external-priority patent/WO2020077114A2/en
Publication of JP2022512689A publication Critical patent/JP2022512689A/ja
Publication of JP2022512689A5 publication Critical patent/JP2022512689A5/ja
Application granted granted Critical
Publication of JP7577650B2 publication Critical patent/JP7577650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520223A 2018-10-10 2019-10-10 ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 Active JP7577650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744069P 2018-10-10 2018-10-10
US62/744,069 2018-10-10
PCT/US2019/055679 WO2020077114A2 (en) 2018-10-10 2019-10-10 Disulfide bond stabilized polypeptide compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2022512689A JP2022512689A (ja) 2022-02-07
JP2022512689A5 true JP2022512689A5 (cg-RX-API-DMAC7.html) 2022-09-21
JP7577650B2 JP7577650B2 (ja) 2024-11-05

Family

ID=68425288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520223A Active JP7577650B2 (ja) 2018-10-10 2019-10-10 ジスルフィド結合により安定したポリペプチド組成物及びその使用方法

Country Status (17)

Country Link
US (3) US11097015B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863663A2 (cg-RX-API-DMAC7.html)
JP (1) JP7577650B2 (cg-RX-API-DMAC7.html)
KR (1) KR102743734B1 (cg-RX-API-DMAC7.html)
CN (1) CN113631182B (cg-RX-API-DMAC7.html)
AR (1) AR116624A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019359385B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006829A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115944A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000883A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190999A1 (cg-RX-API-DMAC7.html)
IL (1) IL282205A (cg-RX-API-DMAC7.html)
MX (1) MX2021004188A (cg-RX-API-DMAC7.html)
PH (1) PH12021550789A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103640VA (cg-RX-API-DMAC7.html)
TW (1) TW202027781A (cg-RX-API-DMAC7.html)
WO (1) WO2020077114A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
AU2021356684A1 (en) * 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
AR124981A1 (es) * 2021-02-26 2023-05-24 Takeda Pharmaceuticals Co Composición y métodos para el tratamiento de la enfermedad de fabry
AU2022388800A1 (en) * 2021-11-12 2024-06-27 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of mucopolysaccharidosis iiia
US20250034533A1 (en) * 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA
US20240408157A1 (en) * 2021-12-02 2024-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
AU2024241509A1 (en) * 2023-03-20 2025-09-25 Spark Therapeutics, Inc. Ppt1 gene therapy
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease
WO2025264978A2 (en) 2024-06-20 2025-12-26 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a proteins and gene therapy

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031113A1 (en) 1998-11-24 2000-06-02 Bristol-Myers Squibb Company INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1118334A1 (en) 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
JP4979067B2 (ja) 2003-05-01 2012-07-18 ジェンザイム・コーポレーション 神経代謝性疾患についての遺伝子治療
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1689766B1 (en) 2003-11-06 2012-04-25 Danisco US Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
ATE474917T1 (de) 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2687597B1 (en) 2011-03-16 2018-12-26 Amano Enzyme Inc. Modified alpha-glucosidase and applications of same
LT2714752T (lt) 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
WO2014022515A1 (en) * 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
EP2976092B1 (en) 2013-03-15 2020-04-22 Amicus Therapeutics, Inc. Chemical crosslinkers
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
TW202344691A (zh) 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法

Similar Documents

Publication Publication Date Title
TWI920044B (zh) 用於治療龐貝症及溶酶體病症之包含肝特異性啟動子之治療性腺相關病毒
ES2371913T3 (es) Constructos mejorados para expresar polipéptidos lisosomales.
TWI808169B (zh) 基因治療構築體及使用方法
JP2021521851A5 (cg-RX-API-DMAC7.html)
CN113631182B (zh) 二硫键稳定的多肽组合物和使用方法
CA3133453A1 (en) Recombinant adeno-associated virus vectors
CA3120105A1 (en) Therapeutic adeno-associated virus for treating pompe disease
US20220133906A1 (en) Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal teargeting sequence
JP2022552254A (ja) バリアントigf2構築体
CN119876200A (zh) 密码子优化的补体因子i
AU2021273273A1 (en) Compositions useful for treatment of pompe disease
JP2024519819A (ja) 眼疾患および障害を処置するための方法および組成物
US20240271115A1 (en) Methods and compositions for depleting antibodies
US20240318157A1 (en) Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide
KR20250110842A (ko) 대사질환을 위한 유전자 요법 구성체
JP2025515030A5 (cg-RX-API-DMAC7.html)
US20220347315A1 (en) Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins
EP4516913A1 (en) Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced
KR102814185B1 (ko) 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
JP2024546578A5 (cg-RX-API-DMAC7.html)
HK40053744A (zh) 二硫键稳定的多肽组合物和使用方法
HK40039189A (en) Gene therapy constructs and methods of use
KR20250080845A (ko) 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
RU2021101685A (ru) Оптимизированные гены cln5 и кассеты для их экспрессии, и их применение
HK40053744B (en) Disulfide bond stabilized polypeptide compositions and methods of use